Aptabio Therapeutics

At a glance

Aptabio Therapeutics filed 29 disclosures in the last 12 months.

Revenue for 2025 was ₩3.7B, up 10% on 2024. It made an operating loss of ₩15.8B. Debt was 27% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩2.6B and operating loss of ₩9.7B.

The 2025 annual report lists 45 employees with an average tenure of 2.7 years and average pay of ₩57.7M. Its 5 directors and auditors were paid ₩201.6M each on average. It paid no cash dividend for 2025. 이수진 and related parties held 27.22% at year end.

From the 2025 annual report

Staff: 45 (17 men, 28 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.2B. Directors and auditors: 5, paid ₩1B in total.

No cash dividend was paid for 2025.

Largest shareholder

이수진 holds 17.42%; with 4 related parties the group holds 27.22% of common shares at year end (from 28.45% at the start of the year).

Auditor: 정진세림회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary